Back to homepage Our offer: Strain collections

Large strain collections available for your projects!

Are you looking for specific strains? Smaltis and its network of partners will do everything to find them for you!

Indeed, Smaltis offers you the provision of bacterial or fungal strains from various collections, with the aim of allowing you to use microbial resources specifically tailored to your needs. These strains can be used directly in the manipulations we implement for your projects, or, in some cases, they can be transmitted to you so that you can carry out your experiments successfully.

Patient-Derived Strains

Through its exclusive collaboration with the Biologic Resource Center – Filière Microbiologique de Besançon (CRB-FMB) at the Jean Minjoz University Hospital, Smaltis provides access to over 80,000 strains isolated from hospitalized patients suffering from various pathologies. These clinical isolates are cataloged based on geography, year of isolation, antibiotic resistance phenotype, sample source, and patient demographic data. Each strain is accompanied by the date and sampling conditions, patient’s clinical status and whether antibiotic therapy was prescribed or not.

Reference Strains

Furthermore, Smaltis offers the opportunity to conduct work on reference strains sourced from various bioresources. Among the species we already possess are Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, Escherichia coli, and various Enterobacter species.

Genetically Modified Bacterial Strains

Through its expertise in molecular biology, Smaltis has established collections of genetically modified bacterial strains that can be used in your projects. These strains are characterized both phenotypically and genotypically.

Strains for Early Antibiotic resistance Study

Since its establishment, Smaltis has been building proprietary mutant banks specific to different species such as Pseudomonas aeruginosa, Escherichia coli, and Klebsiella pneumoniae. These mutants exhibit different antibiotic resistance profiles and are characterized within well-controlled genetic backgrounds. Among the targeted resistance mechanisms are active efflux, enzyme production, and antibiotic target mutations. These mutant banks, designed specifically for the early study of the role and nature of resistance mechanisms commonly found in clinical settings, allow for anticipating the adaptation of microorganisms to future antimicrobial molecules.

Strains for Bioproduction

In addition to the study of antibiotic resistance, Smaltis also invests in the development of tools for bioproduction. Consequently, Smaltis owns a strain of Escherichia coli BL21 with deleted genes encoding for phage DE3, constructed on animal-free media.
Smaltis also possesses a chassis derived from the reference strain of Pseudomonas aeruginosa PAO1, which is hypersensitive to antibiotics and hypovirulent. Additionally, finely controlled and inducible expression plasmids are available. These tools are accessible through licensing for commercial activities.
If your desired strain is not available in the catalog, we can tailor-build it for you! (see our Genetic Engineering offer)

Support Service: Strain and Product Storage

Additionally, Smaltis offers dedicated storage space specifically designed for microorganisms and pharmaceutical products, available for an unlimited duration. This storage is maintained at a controlled temperature of -80°C, with a continuous alarm system.

This storage solution enables you to have a secure backup of your bacterial or fungal strains or to store pharmaceutical products until they are needed. A storage certificate is regularly provided, including details related to the preservation, and is updated with each modification.

This service ensures the longevity and safety of your valuable microbial resources and pharmaceutical products, allowing you to access them whenever necessary, supported by a comprehensive documentation and monitoring system.

Our partners and networks

News and articles

Legionella pneumophila: achieving homogeneity with a bacterium prone to aggregation

In this second episode dedicated to fastidious bacteria, let’s take a closer look at Legionella pneumophila. Its cultivation requires a specific medium, notably enriched with L-cysteine and iron. With this species, medium composition, incubation time, and the timing of readout directly influence bacterial recovery.

READ THE POST

Characterization of PDRN in cosmetic active ingredients

PDRN is attracting growing interest in dermatology, aesthetic medicine, and the development of cosmetic active ingredients. Long associated with preparations derived from salmonids, PDRN is now also being investigated from plant and algal sources. This diversification of raw materials and production processes calls for characterization tailored to each preparation, in order to compare ingredients using documented scientific criteria and support their development.

READ THE POST

Borrelia : quantitative precision at the heart of inoculum preparation

First episode dedicated to fastidious bacteria: Borrelia, the spirochetes responsible for borreliosis, or Lyme disease, for which accurate enumeration directly determines the quality of the inoculum.

At Smaltis, we work in particular with Borrelia afzelii, Borrelia burgdorferi sensu stricto, and Borrelia garinii, three major species of the Borrelia burgdorferi sensu lato complex involved in borreliosis, or Lyme disease.

READ THE POST

Cutibacterium acnes: when the strain matters as much as the species

À la surface de notre peau et au cœur des follicules pilo-sébacés vit une bactérie bien connue : Cutibacterium acnes. Particulièrement abondante dans les zones riches en sébum, cette bactérie à Gram positif et anaérobie aérotolérante est fréquemment associée à l’acné.

Pourtant, sa présence n’est pas en elle-même le signe d’un déséquilibre. C. acnes fait partie du microbiote cutané normal et se retrouve aussi bien sur une peau saine que sur une peau à tendance acnéique. Certaines études ont même montré que son abondance globale pouvait être relativement comparable dans ces deux situations.

Le rôle de C. acnes ne peut donc pas être compris en recherchant uniquement sa présence ou en mesurant sa quantité. Il dépend également de la composition de sa population, des propriétés des souches qui la constituent et de leurs interactions avec leur environnement.

READ THE POST

Resistance of Pseudomonas aeruginosa to odilorhabdins: MexXY(OprM) at the heart of the bacterial response

Why can an antibiotic active against several Gram-negative bacteria lose much of its efficacy against Pseudomonas aeruginosa?

A study published in 2026 in Microbiology Spectrum, to which Smaltis contributed, provides new insights into this question. It shows that the MexXY(OprM) efflux pump plays a major role in the resistance of P. aeruginosa to odilorhabdins, a new class of antibiotics targeting the bacterial ribosome.

Beyond this finding, the study illustrates an essential reality in the development of new antimicrobials: knowing a compound’s target is not enough. It is also necessary to understand how the bacterium detects it, adapts to it, and organises its defence

READ THE POST

Choosing the Right Strain to Build a Relevant Microbiological Model

In microbiology, a strain is never just another component of a protocol. It carries a genome, a history and an origin that determine what an experiment can truly reveal. Two strains belonging to the same species can therefore generate different results, all technically valid, yet not necessarily answering the same scientific question.

This is why, at Smaltis, strain selection is an integral part of experimental design. Before searching a collection or looking for a specific isolate, we first clarify the objective of the project: is the aim to standardize a method, understand a mechanism, evaluate an antimicrobial compound, reproduce a resistance phenotype, or represent a clinical situation? The answer then determines the most appropriate model: a reference strain, a human, veterinary or environmental isolate, a strain panel, an available mutant, or a custom-built strain.

READ THE POST

Once upon a time… the smell of rain

Once upon a time, there was a scent so familiar that it was given its own name: petrichor.
It is the unmistakable fragrance that rises from the ground after the first drops of a summer rain fall onto dry soil. A comforting, almost universal scent that evokes woodland walks, gardens after a thunderstorm, or cherished childhood memories.
For centuries, people simply believed it was the smell of wet earth. The truth, however, proved far more fascinating.

READ THE POST

Management of Microbiological Contamination: Identifying, Understanding and Preventing Recurrence

Microbiological contamination is not limited to a non-compliant result. In R&D development, quality control, an industrial process or biological production, it immediately raises concrete questions: where does the contaminant come from, is it isolated or recurrent, what is its impact, and how can its reappearance be prevented?

The response is not simply to identify the bacterium and then restart the process. To achieve lasting control of bacterial contamination, the investigation must be able to connect laboratory observations with the real operational context: samples, flows, raw materials, equipment, cleaning, disinfection and field practices.

At Smaltis, we approach these situations as a structured microbiological investigation: understanding the problem, isolating the contaminants, identifying and comparing the isolates, preserving useful material, and then testing appropriate prevention solutions.

READ THE POST

Skin Microbiome: Cultivating Rigor to Objectify Innovation

The skin microbiome is not mere scenery. It is a functional component of the skin, involved in protection against pathogens, immune dialogue, and the modulation of inflammation. It is a dynamic ecosystem shaped by subtle interactions between bacteria, yeasts, the host, and the environment.

Our approach is grounded in a simple conviction: understanding a microbiome is not merely about identifying it. It is about knowing how to culture it, interrogate it, and generate scientifically defensible data.

This is precisely how we approach the skin microbiome: as a complex ecosystem whose actors, dynamics, and mechanisms must be mastered before attempting to modulate its balance.

READ THE POST

The Story of a Microbiota That Became a Medicine

Once upon a time, in the hospitals of the twenty-first century, there was an infection that even antibiotics could no longer silence. An opportunistic infection caused by a bacterium called Clostridioides difficile, it often appeared in patients who were already vulnerable… and, above all, already heavily treated. Let us look back at the history of this infection, which gave rise to new therapeutic approaches.

READ THE POST

Let's study your project!

Are you interested in our services? Ask our experts to study your needs and design a tailor-made collaboration with you.

Book a discovery call